Piper Sandler Maintains Overweight on Immunome, Lowers Price Target to $30

Benzinga · 2d ago
Piper Sandler analyst Biren Amin maintains Immunome (NASDAQ:IMNM) with a Overweight and lowers the price target from $33 to $30.